Cyclotron production of manganese-52: a promising avenue for multimodal PET/MRI imaging

• Published in: EJNMMI radiopharmacy and chemistry Vol. 9; no. 1; pp. 57 - 19
• Main Authors: Porto, Francesca, Cisternino, Sara, Cazzola, Emiliano, Speltri, Giorgia, Mou, Liliana, Boschi, Alessandra, Marvelli, Lorenza, Di Domenico, Giovanni, Pagnoni, Antonella, De Dominicis, Lucia, Calliari, Irene, Gennari, Claudio, Uccelli, Licia, Pupillo, Gaia, Gorgoni, Giancarlo, Esposito, Juan, Martini, Petra
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 02.08.2024; Springer Nature B.V; SpringerOpen
• Subjects: Chelating agents; Chemistry; Chromium; Contrast agents; Cyclotron production; Imaging; Imaging techniques; In vivo methods and tests; Ion exchange chromatography; Isotopes; Magnetic resonance imaging; Manganese; Manganese-52; Manufacturing; Medical imaging; Medicine; Medicine & Public Health; Mn-radiopharmaceuticals; Molecular Medicine; Nuclear Chemistry; Nuclear Medicine; PET/MRI; Pharmaceuticals; Pharmacotherapy; Physics; Plasma sintering; Positron emission; Positron emission tomography; Radioisotopes; Radiology; Research Article; Sensory integration; Spark plasma sintering; Tomography; Toxicity; Mn-based contrast agents; Cyclotron production; Spark plasma sintering; PET/MRI; Manganese-52; PET-imaging; Mn-radiopharmaceuticals; Ion exchange chromatography
• ISSN: 2365-421X; 2365-421X
• DOI: 10.1186/s41181-024-00288-6

Background The integration of positron emission tomography (PET) and magnetic resonance imaging (MRI) holds promise for advancing diagnostic imaging capabilities. The METRICS project aims to develop cyclotron-driven production of 52 Mn for PET/MRI imaging. Results Using the 52 Cr(p,n) 52 Mn reaction, we designed chromium metal targets via Spark Plasma Sintering and developed a separation procedure for isolating 52 Mn. Labeling tests were conducted with traditional chelators (i.e. S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid) and the 1.4-dioxa-8-azaspiro[4.5]decane-8- carbodithioate ligand to produce radioactive complexes suitable for PET/MRI applications. Our methodology yielded high-quality 52 Mn suitable for PET radiopharmaceuticals and PET/MRI imaging. Preliminary studies on phantom imaging using microPET and clinical MRI demonstrated the efficacy of our approach. Conclusions The developed technology offers a promising avenue for producing 52 Mn and enhancing PET/MRI imaging capabilities. Further in vivo investigations are warranted to evaluate the potential advantages of this hybrid imaging technique.